Compare · GKOS vs RMD
GKOS vs RMD
Side-by-side comparison of Glaukos Corporation (GKOS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 3.2x GKOS ($10.70B).
- Over the past year, GKOS is up 93.4% and RMD is down 17.0% - GKOS leads by 110.4 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 6 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- ResMed Inc.
- Price
- -
- -
- Market cap
- $10.70B
- $34.13B
- 1M return
- +19.27%
- +16.50%
- 1Y return
- +93.37%
- -17.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest GKOS
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)
- Glaukos Announces Participation in Wells Fargo Healthcare Conference
- PRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)
- Director Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)
- Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Glaukos Corporation
- Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Glaukos Announces Second Quarter 2026 Financial Results
- UBS initiated coverage on Glaukos
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)